Attached files
| file | filename |
|---|---|
| EX-10.26 - EX-10.26 - SANGAMO THERAPEUTICS, INC | sgmo-20191231xexx1026.htm |
| EX-10.25 - EX-10.25 - SANGAMO THERAPEUTICS, INC | sgmo-20191231xexx1025.htm |
| EX-4.1 - EX-4.1 - SANGAMO THERAPEUTICS, INC | sgmo-20191231xexx41.htm |
| EX-23.1 - EX-23.1 - SANGAMO THERAPEUTICS, INC | sgmo-20191231xexx231.htm |
| EX-10.45 - EX-10.45 - SANGAMO THERAPEUTICS, INC | sgmo-20191231xexx1045.htm |
| EX-10.24 - EX-10.24 - SANGAMO THERAPEUTICS, INC | sgmo-20191231xexx1024.htm |
| EX-31.2 - EX-31.2 - SANGAMO THERAPEUTICS, INC | sgmo-20191231xex312.htm |
| EX-31.1 - EX-31.1 - SANGAMO THERAPEUTICS, INC | sgmo-20191231xex311.htm |
| EX-32.1 - EX-32.1 - SANGAMO THERAPEUTICS, INC | sgmo-20191231xex321.htm |
| 10-K - 10-K - SANGAMO THERAPEUTICS, INC | sgmo-20191231.htm |
Exhibit 21.1
Subsidiaries of the Company
Gendaq Limited (U.K.)
Ceregene Inc. (Delaware)
Sangamo Therapeutics France S.A.S. (France)